In this issue of PLOS Biology, Kreher and colleagues show in a mouse model that in vivo, neurons and not only myelinating glia are primary effectors of disease progression in Krabbe disease. The neuron-specific model generated allows the unprecedented capacity to investigate the neuronal autonomous component of this disorder.
Citation: Brites P, Sousa MM (2022) Neurons contribute to pathology in a mouse model of Krabbe disease in a cell-autonomous manner. PLoS Biol 20(7): e3001706. https://doi.org/10.1371/journal.pbio.3001706
Published: July 6, 2022
Copyright: © 2022 Brites, Sousa. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Work from the authors in the field of leukodystrophies is supported by FEDER - Fundo Europeu de Desenvolvimento Regional funds through the NORTE 2020 - Norte Portugal Regional Operational Programme, Portugal 2020, and by Portuguese funds through FCT - Fundação para a Ciência e a Tecnologia/Ministério da Ciência, Tecnologia e Ensino Superior (PTDC/MED-PAT/30558/2017; NORTE-01-0145-FEDER-030558 to P.B and EJPRD/0002/2019 to M.M.S.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Abbreviations: CNS, central nervous system; GALC, galactosylceramidase; PNS, peripheral nervous system; WT, wild-type
In Krabbe disease, also known as globoid cell leukodystrophy, mutations in β-galactosylceramidase (GALC), a lysosomal enzyme responsible for the catabolism of myelin galactolipids, lead to the accumulation of its substrates galactocerebroside and psychosine [1]. Whereas galactocerebroside builds up inside macrophages and microglia giving rise to globoid cells, psychosine accumulates in myelinating glia culminating in demyelination and is therefore considered the main culprit of the disorder. The estimated incidence of Krabbe disease ranges from 1:250,000 in the United States of America to 1:100,000 in Europe and 1:100 in some communities with high consanguinity. The most common form of the disorder is infantile, although late onset and adult forms of Krabbe disease also occur. In infants, the disorder is generally diagnosed before 6 months of age, and symptoms are very severe including irritability, stiffness, loss of vision and hearing, seizures, and paralysis. In the absence of treatment, disease progression is very rapid with death occurring within 2 to 3 years given organ failure as a result of demyelination. In late onset patients, symptoms have a more variable onset and disease progression is usually slower. The Twitcher mouse, a naturally occurring model of Krabbe disease (with a W355* nonsense mutation that abolishes enzymatic activity), mimics the infantile form of the disorder. In Twitcher mice, in agreement with the ubiquitous nature of Galc expression, psychosine accumulates in myelinating glia and neurons [2]. As a possible consequence of psychosine accumulation in neurons, axonal swellings [2] and axonal loss [3] occur in the Twitcher nervous system before the onset of demyelination, supporting a myelin-independent dying-back neuropathy. The existence of neuronal deposits of α-synuclein in Twitcher mice and human Krabbe samples [4], and the fact that induced neurons from Krabbe patient’s fibroblasts present axonal defects [5], further contributed to support that neurons are an important neglected cell type primarily affected in this disorder. However, in the above models, given the ubiquity of Galc, the final proof of the neuron-autonomous nature of the defects observed remains to be provided, as one cannot exclude the contribution of alternative cells to the neuronal pathology, nor a putative prior conditioning of cultured neurons.
In this issue of PLOS Biology, Kreher and colleagues use the recently generated conditional Galc floxed mouse [6] to eliminate Galc from neurons and investigate the existence of a neuron-autonomous role for Galc. In the genetic background of Galc heterozygosity (Galcf/−), neuronal ablation was achieved by Synapsin 1–mediated expression of cre recombinase. The homozygous loss of Galc in neurons (Syn1Cre:Galcf/−) is shown to be sufficient to induce a neurological phenotype with growth and motor-coordination defects. The analysis of Syn1Cre:Galcf/− mice revealed that psychosine accumulates in the nervous system where neuronal and axon degeneration, neuroinflammation (astrocytosis and microgliosis), and a mild reduction in myelination occur (Fig 1). Thus, this publication underscores that neuronal Galc is essential for normal central nervous system (CNS) homeostasis and directly contributes to the pathogenesis of Krabbe disease. A limitation of this study is however the use of a generalized Galc heterozygosity background (Galc+/−), in which all murine cells only have one functional Galc allele. Although Galc+/− mice do not develop an overt phenotype or pathology, and express normal levels of several myelin components, Galc heterozygosity causes a reduction in Galc activity [6], impaired microglial function, and defective repair of myelin damage [7]. Thus, studies using Galcf/f mice in a wild-type (WT) background would serve to fully decouple effects of loss of Galc activity in neurons from possible mild consequences of Galc heterozygosity.
[Figure omitted. See PDF.]
Fig 1. Affected cells in the CNS of Syn1Cre:Galcf/− mice.
Representation (left) of a WT neuron within a CNS populated with myelinating oligodendrocytes, resting microglia, and astrocytes. Representation (right) of a Syn1Cre:Galcf/− neuron within the CNS populated by Galc+/− heterozygous (Htz) cells. The neuronal Galc deficiency causes distal degeneration of axons and a generalized astrocytic and microglial response. Activated microglia (appear more amoeboid-shaped) and activated astrocytes (hypertrophic) are observed in the CNS of Syn1Cre:Galcf/− mice, possibly due to the ongoing neurodegeneration. The neuronal Galc deficiency also affects Galc+/− oligodendrocytes, as they display reduced amounts of MBP and MAG and thinner myelin sheaths. CNS, central nervous system; MAG, myelin-associated glycoprotein; MBP, myelin basic protein; WT, wild-type.
https://doi.org/10.1371/journal.pbio.3001706.g001
The findings of Kreher and colleagues underscore the need to further understand the specific cellular and molecular mechanisms of GALC function in neurons. A substantial body of data already shows the cell-specific deleterious effects of psychosine in this cell type. Psychosine can intercalate in membrane lipid rafts disrupting their structure and, as a consequence, impairing lipid-raft mediated signaling, including critical pathways for neuronal development and function such as PKC, Erk, and AKT-GSK3β [3,8,9]. In addition, psychosine accumulation in neurons also impairs endocytosis and axonal transport [3,8], whose tightly regulated balance is critical for normal neuronal biology and function. It is also essential to consider that neuronal-derived psychosine may influence neighboring nonneuronal cells by being carried in extracellular vesicles, as recently shown in Twitcher mice [10]. Beyond psychosine, galactosylceramide (that is also GALC substrate) and its biosynthetic enzyme (UDP galactosyltransferase 8A - UGT8a), are generally viewed as oligodendrocyte specific. In this respect, it is possible that neuronal galactosylceramide might be transferred to neurons from neighboring myelinating cells. Finally, one should take into account that if axonal survival is critically dependent on supporting glia, healthy functional axons are also required for the maintenance of fit myelinating glia. By showing that the neuronal-specific deletion of GALC in neurons leads to neuroinflammation and mild myelin loss, Kreher and colleagues’ findings reinforce the need to further focus on the neuron-glial crosstalk in the context of leukodystrophies.
In summary, in this issue of PLOS Biology, the study of Kreher and colleagues opens new windows of action in Krabbe disease by highlighting that in vivo neurons are an important primary cellular target in this disorder. Although originally classified as a myelin disorder—leukodystrophy—in which the involvement of CNS and peripheral nervous system (PNS) myelin mediated a secondary neurodegeneration, there is now mounting evidence of an additional neuron-autonomous effect behind Galc deficiency. It is possible that similar cell-autonomous mechanisms unrelated to myelinating glia operate in other leukodystrophies, especially for those in which the disease-causing gene shows generalized expression in multiple cell types. Thus, not only new therapeutic strategies focused on targeting and correcting primary neuronal defects but also further knowledge on cell-specific primary effects caused by the accumulation of toxic substrates in different cell types of the nervous system are needed in Krabbe disease and also in other leukodystrophies.
Citation: Brites P, Sousa MM (2022) Neurons contribute to pathology in a mouse model of Krabbe disease in a cell-autonomous manner. PLoS Biol 20(7): e3001706. https://doi.org/10.1371/journal.pbio.3001706
1. Feltri ML, Weinstock NI, Favret J, Dhimal N, Wrabetz L, Shin D. Mechanisms of demyelination and neurodegeneration in globoid cell leukodystrophy. Glia. 2021;69(10):2309–31. pmid:33851745
2. Castelvetri LC, Givogri MI, Zhu H, Smith B, Lopez-Rosas A, Qiu X, et al. Axonopathy is a compounding factor in the pathogenesis of Krabbe disease. Acta Neuropathol. 2011;122(1):35–48. pmid:21373782
3. Teixeira CA, Miranda CO, Sousa VF, Santos TE, Malheiro AR, Solomon M, et al. Early axonal loss accompanied by impaired endocytosis, abnormal axonal transport, and decreased microtubule stability occur in the model of Krabbe’s disease. Neurobiol Dis. 2014;66:92–103. pmid:24607884
4. Smith BR, Santos MB, Marshall MS, Cantuti-Castelvetri L, Lopez-Rosas A, Li G, et al. Neuronal inclusions of alpha-synuclein contribute to the pathogenesis of Krabbe disease. J Pathol. 2014;232(5):509–21. pmid:24415155
5. Lim SM, Choi BO, Oh SI, Choi WJ, Oh KW, Nahm M, et al. Patient fibroblasts-derived induced neurons demonstrate autonomous neuronal defects in adult-onset Krabbe disease. Oncotarget. 2016;7(46):74496–509. pmid:27780934
6. Weinstock NI, Kreher C, Favret J, Nguyen D, Bongarzone ER, Wrabetz L, et al. Brainstem development requires galactosylceramidase and is critical for pathogenesis in a model of Krabbe disease. Nat Commun. 2020;11(1):5356. pmid:33097716
7. Scott-Hewitt NJ, Folts CJ, Noble MD. Heterozygous carriers of galactocerebrosidase mutations that cause Krabbe disease have impaired microglial function and defective repair of myelin damage. Neural Regen Res. 2018;13(3):393–401. pmid:29623914
8. Cantuti Castelvetri L, Givogri MI, Hebert A, Smith B, Song Y, Kaminska A, et al. The sphingolipid psychosine inhibits fast axonal transport in Krabbe disease by activation of GSK3beta and deregulation of molecular motors. J Neurosci. 2013;33(24):10048–56. pmid:23761900
9. White AB, Givogri MI, Lopez-Rosas A, Cao H, van Breemen R, Thinakaran G, et al. Psychosine accumulates in membrane microdomains in the brain of krabbe patients, disrupting the raft architecture. J Neurosci. 2009;29(19):6068–77. pmid:19439584
10. Reiter CR, Rebiai R, Kwak A, Marshall J, Wozniak D, Scesa G, et al. The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease. ASN Neuro. 2022;14:17590914221087817. pmid:35300522
About the Authors:
Pedro Brites
Affiliation: Neurolipid Biology Group, Instituto de Biologia Molecular e Celular (IBMC), Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal
Monica M. Sousa
* E-mail: [email protected]
Affiliation: Nerve Regeneration Group, Instituto de Biologia Molecular e Celular (IBMC), Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal
ORCID logo https://orcid.org/0000-0002-4524-2260
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2022 Brites, Sousa. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
In this issue of PLOS Biology, Kreher and colleagues show in a mouse model that in vivo, neurons and not only myelinating glia are primary effectors of disease progression in Krabbe disease. The neuron-specific model generated allows the unprecedented capacity to investigate the neuronal autonomous component of this disorder.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer